Living Cell Technologies Limited Logo

Living Cell Technologies Limited

LVCLF

(0.8)
Stock Price

0,01 USD

-113.45% ROA

-54.06% ROE

-2.42x PER

Market Cap.

8.769.028,35 USD

0% DER

0% Yield

0% NPM

Living Cell Technologies Limited Stock Analysis

Living Cell Technologies Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Living Cell Technologies Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-72.33%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-45.79%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.34x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Living Cell Technologies Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Living Cell Technologies Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Buy
4 Stoch RSI Hold

Living Cell Technologies Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Living Cell Technologies Limited Revenue
Year Revenue Growth
2004 72.714
2005 65.412 -11.16%
2006 1.307 -4904.74%
2007 18.292 92.85%
2008 51.946 64.79%
2009 186.463 72.14%
2010 517.087 63.94%
2011 176.538 -192.9%
2012 3.708.000 95.24%
2013 7.580.000 51.08%
2014 7.394.130 -2.51%
2015 611.955 -1108.28%
2016 120.091 -409.58%
2017 115.279 -4.17%
2018 121.403 5.04%
2019 9.769 -1142.74%
2020 3.168 -208.36%
2021 268.184 98.82%
2022 3.405 -7776.18%
2023 42.016 91.9%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Living Cell Technologies Limited Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 1.369.147 100%
2006 1.071.512 -27.78%
2007 1.148.518 6.7%
2008 651.033 -76.41%
2009 1.265.145 48.54%
2010 1.458.674 13.27%
2011 5.059.381 71.17%
2012 2.620.000 -93.11%
2013 396.000 -561.62%
2014 487.356 18.75%
2015 1.774.381 72.53%
2016 2.364.452 24.96%
2017 4.441.754 46.77%
2018 3.502.378 -26.82%
2019 3.328.905 -5.21%
2020 2.383.801 -39.65%
2021 1.609.230 -48.13%
2022 1.463.134 -9.99%
2023 1.309.600 -11.72%
2024 1.333.952 1.83%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Living Cell Technologies Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 917.360
2005 3.117.759 70.58%
2006 4.035.865 22.75%
2007 3.949.645 -2.18%
2008 3.480.349 -13.48%
2009 3.716.562 6.36%
2010 3.722.013 0.15%
2011 3.690.319 -0.86%
2012 1.808.000 -104.11%
2013 1.263.000 -43.15%
2014 1.706.590 25.99%
2015 1.541.851 -10.68%
2016 1.632.353 5.54%
2017 1.846.248 11.59%
2018 1.770.426 -4.28%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Living Cell Technologies Limited EBITDA
Year EBITDA Growth
2004 -2.080.790
2005 -5.943.110 64.99%
2006 -6.629.405 10.35%
2007 -5.495.765 -20.63%
2008 -6.397.365 14.09%
2009 -7.551.098 15.28%
2010 -6.685.465 -12.95%
2011 -8.573.162 22.02%
2012 5.802.000 247.76%
2013 -2.962.000 295.88%
2014 -6.758.638 56.17%
2015 -7.032.114 3.89%
2016 -3.986.701 -76.39%
2017 -5.177.322 23%
2018 -4.208.620 -23.02%
2019 -4.110.025 -2.4%
2020 -3.145.950 -30.64%
2021 -2.278.844 -38.05%
2022 -2.363.746 3.59%
2023 -2.128.930 -11.03%
2024 -2.798.000 23.91%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Living Cell Technologies Limited Gross Profit
Year Gross Profit Growth
2004 72.714
2005 65.412 -11.16%
2006 1.307 -4904.74%
2007 18.292 92.85%
2008 51.946 64.79%
2009 186.463 72.14%
2010 517.087 63.94%
2011 176.538 -192.9%
2012 285.000 38.06%
2013 513.000 44.44%
2014 618.644 17.08%
2015 30.380 -1936.35%
2016 10.104 -200.67%
2017 115.279 91.24%
2018 121.403 5.04%
2019 9.769 -1142.74%
2020 3.168 -208.36%
2021 218.870 98.55%
2022 2.662 -8122.01%
2023 41.459 93.58%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Living Cell Technologies Limited Net Profit
Year Net Profit Growth
2004 0
2005 0 0%
2006 -6.819.611 100%
2007 -5.987.322 -13.9%
2008 -6.794.037 11.87%
2009 -6.123.562 -10.95%
2010 -5.674.059 -7.92%
2011 -6.795.708 16.51%
2012 5.676.000 219.73%
2013 -2.979.000 290.53%
2014 -6.778.896 56.05%
2015 -7.043.402 3.76%
2016 -3.093.163 -127.71%
2017 -4.090.257 24.38%
2018 -374.492 -992.21%
2019 -3.181.363 88.23%
2020 -968.469 -228.49%
2021 -1.460.591 33.69%
2022 -1.957.300 25.38%
2023 -2.107.658 7.13%
2024 -2.577.888 18.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Living Cell Technologies Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Living Cell Technologies Limited Free Cashflow
Year Free Cashflow Growth
2004 -2.007.505
2005 -6.558.642 69.39%
2006 -6.867.801 4.5%
2007 -5.693.842 -20.62%
2008 -5.781.473 1.52%
2009 -8.067.146 28.33%
2010 -6.143.423 -31.31%
2011 -5.917.733 -3.81%
2012 -2.529.000 -133.99%
2013 1.317.000 292.03%
2014 -84.531 1658.01%
2015 -3.615.180 97.66%
2016 -3.439.495 -5.11%
2017 -3.619.340 4.97%
2018 -3.573.296 -1.29%
2019 -2.043.845 -74.83%
2020 -3.109.785 34.28%
2021 -1.461.523 -112.78%
2022 -2.046.007 28.57%
2023 -1.986.291 -3.01%
2024 -514.707 -285.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Living Cell Technologies Limited Operating Cashflow
Year Operating Cashflow Growth
2004 -1.272.003
2005 -6.094.932 79.13%
2006 -6.610.850 7.8%
2007 -5.536.559 -19.4%
2008 -5.598.158 1.1%
2009 -5.703.572 1.85%
2010 -5.863.818 2.73%
2011 -5.723.151 -2.46%
2012 -2.487.000 -130.12%
2013 1.337.000 286.01%
2014 -82.441 1721.77%
2015 -3.587.334 97.7%
2016 -3.157.129 -13.63%
2017 -3.370.078 6.32%
2018 -3.570.306 5.61%
2019 -1.990.530 -79.36%
2020 -3.109.785 35.99%
2021 -1.461.523 -112.78%
2022 -2.042.204 28.43%
2023 -1.986.291 -2.81%
2024 -514.707 -285.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Living Cell Technologies Limited Capital Expenditure
Year Capital Expenditure Growth
2004 735.502
2005 463.710 -58.61%
2006 256.951 -80.47%
2007 157.283 -63.37%
2008 183.315 14.2%
2009 2.363.574 92.24%
2010 279.605 -745.33%
2011 194.582 -43.7%
2012 42.000 -363.29%
2013 20.000 -110%
2014 2.090 -856.94%
2015 27.846 92.49%
2016 282.366 90.14%
2017 249.262 -13.28%
2018 2.990 -8236.52%
2019 53.315 94.39%
2020 0 0%
2021 0 0%
2022 3.803 100%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Living Cell Technologies Limited Equity
Year Equity Growth
2004 -1.325.415
2005 3.135.554 142.27%
2006 1.743.610 -79.83%
2007 1.401.328 -24.43%
2008 11.527.248 87.84%
2009 5.527.390 -108.55%
2010 6.239.622 11.41%
2011 6.760.236 7.7%
2012 14.353.000 52.9%
2013 13.252.000 -8.31%
2014 8.431.577 -57.17%
2015 5.126.863 -64.46%
2016 5.676.660 9.69%
2017 7.518.340 24.5%
2018 7.135.323 -5.37%
2019 4.138.491 -72.41%
2020 2.878.354 -43.78%
2021 1.377.116 -109.01%
2022 4.034.824 65.87%
2023 3.762.103 -7.25%
2024 3.014.250 -24.81%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Living Cell Technologies Limited Assets
Year Assets Growth
2004 1.309.448
2005 3.944.714 66.8%
2006 4.258.164 7.36%
2007 3.817.446 -11.54%
2008 12.241.442 68.82%
2009 6.500.029 -88.33%
2010 6.943.366 6.39%
2011 7.471.632 7.07%
2012 15.523.000 51.87%
2013 14.218.000 -9.18%
2014 9.664.604 -47.11%
2015 5.464.515 -76.86%
2016 6.312.458 13.43%
2017 8.694.360 27.4%
2018 7.608.793 -14.27%
2019 5.759.621 -32.11%
2020 3.391.077 -69.85%
2021 1.642.197 -106.5%
2022 4.274.080 61.58%
2023 4.211.959 -1.47%
2024 3.192.698 -31.92%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Living Cell Technologies Limited Liabilities
Year Liabilities Growth
2004 2.634.863
2005 809.160 -225.63%
2006 2.514.554 67.82%
2007 2.416.118 -4.07%
2008 714.194 -238.3%
2009 972.639 26.57%
2010 703.744 -38.21%
2011 711.396 1.08%
2012 1.170.000 39.2%
2013 966.000 -21.12%
2014 1.233.027 21.66%
2015 337.652 -265.18%
2016 635.798 46.89%
2017 1.176.020 45.94%
2018 473.470 -148.38%
2019 1.621.130 70.79%
2020 512.723 -216.18%
2021 265.081 -93.42%
2022 239.256 -10.79%
2023 449.856 46.81%
2024 178.448 -152.09%

Living Cell Technologies Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-2.42x
Price To Sales Ratio
417.41x
POCF Ratio
-3.06
PFCF Ratio
-3.06
Price to Book Ratio
2.91
EV to Sales
269.45
EV Over EBITDA
-2.81
EV to Operating CashFlow
-1.98
EV to FreeCashFlow
-1.98
Earnings Yield
-0.41
FreeCashFlow Yield
-0.33
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.01
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.79
ROE
-1.01
Return On Assets
-0.5
Return On Capital Employed
-0.57
Net Income per EBT
1
EBT Per Ebit
0.99
Ebit per Revenue
0
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
62.86
Stock Based Compensation to Revenue
35.37
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.71
Return on Tangible Assets
-1.13
Days Sales Outstanding
743.22
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0.49
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
1.54
Current Ratio
17.89
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
3014250
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Living Cell Technologies Limited Dividends
Year Dividends Growth

Living Cell Technologies Limited Profile

About Living Cell Technologies Limited

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.

CEO
Mr. David Richard Hainsworth
Employee
0
Address
Tower 2
Sydney, 2000

Living Cell Technologies Limited Executives & BODs

Living Cell Technologies Limited Executives & BODs
# Name Age
1 Ms. Jennifer Voon
Company Secretary
70
2 Mr. David Richard Hainsworth
Chief Executive Officer & Executive Chairman
70
3 Dr. Carolyn M. Sue A.M., B.S., Ph.D.
Member of Medical Advisory Board & Chief Medical Officer of NTCELL
70
4 Dr. James A. Mckenna
Chief Scientific Officer
70

Living Cell Technologies Limited Competitors